126587-35-7

Usage

Uses

Used in Pharmaceutical Synthesis:
(S)-METHYL 4-(TERT-BUTOXYCARBONYLAMINO)-5-HYDROXYPENTANOATE is used as a key intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into complex molecular structures. The presence of both ester and amino functionalities allows for a wide range of chemical reactions, facilitating the development of new drugs.
Used in Organic Chemistry:
In the field of organic chemistry, (S)-METHYL 4-(TERT-BUTOXYCARBONYLAMINO)-5-HYDROXYPENTANOATE is utilized as a valuable intermediate due to its capacity to participate in various organic transformations. The tert-butoxycarbonyl protecting group can be removed under mild conditions, enabling further chemical manipulations and the exposure of the amino function for additional reactions.
Used in Bioactive Molecule Synthesis:
(S)-METHYL 4-(TERT-BUTOXYCARBONYLAMINO)-5-HYDROXYPENTANOATE is also used as a precursor in the synthesis of bioactive molecules, where its unique structure and functional groups contribute to the creation of compounds with potential therapeutic or biological activity.

InChI:InChI=1/C11H21NO5/c1-11(2,3)17-10(15)12-8(7-13)5-6-9(14)16-4/h8,13H,5-7H2,1-4H3,(H,12,15)/t8-/m0/s1

Upstream product

• 39538-20-0 (S)-2-tert-Butoxycarbonylamino-pentanedioic acid 1-(2,5-dioxo-pyrrolidin-1-yl) ester 5-methyl ester 
• 45214-91-3 (2S)-2-[(tert-butoxy)carbonylamino]-4-(methoxycarbonyl)butanoic acid 
• 541-41-3 chloroformic acid ethyl ester 
• 59279-60-6 dimethyl (2S)-2-[(tert-butoxycarbonyl)amino]pentanedioate 
• 81658-26-6 tert-butyl (S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-5-oxopyrrolidin-1-carboxylate 
• 96014-55-0 Methyl (4S)-4-(N-(tert-Butoxycarbonyl)amino)-5-((tert-butyldimethylsilyl)oxy)pentanoate 
• 3077-51-8 γ-methyl L-glutamate hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1499-55-4 L-glutamic acid 5-methyl ester 
• 56-86-0 L-glutamic acid 

Downstream Products

• 1422740-22-4 C₃₃H₅₁NO₆Si 
• 1422740-23-5 C₂₈H₃₆N₂O₅ 
• 1422740-24-6 C₃₂H₃₈N₂O₅ 
• 1276112-33-4 C₃₂H₃₉NO₆ 
• 1276112-41-4 C₃₅H₄₃NO₅ 
• 1276112-34-5 C₃₅H₄₃NO₅ 
• 1422740-11-1 C₃₃H₅₁NO₆Si 
• 1333536-82-5 (4S)-4-N-tert-butoxycarbonylamino-5-(triphenylmethylthio)-pentanoic acid allyl ester 
• 1603835-90-0 (S)-N-(1-azidomethyl-4-O-tert-butyldiphenylsilyloxybutyl)-N-2-cyanoethyl diethylphosphonoacetamide 
• 1603835-87-5 (S)-4-amino-5-azido-O-tert-butyldiphenylsilyl-1-pentanol 
• 220623-07-4 (1S,2S,5R)-tert-butyl 3-aza-4-oxo-2-<(1,1,2,2-tetramethyl-1-silapropoxy)methyl>bicyclo<3.1.0>hexane-3-carboxylate 
• 293297-95-7 (5S)-N-(tert-Butoxycarbonyl)-5-(((tert-butyldimethylsilyl)oxy)methyl)-3-(phenylseleno)pyrrolidin-2-one 
• 81658-27-7 (S)-tert-butyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-5-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate 
• 106191-02-0 (S)-5-((tert-butyldimethylsilyloxy)methyl)pyrrolidin-2-one 

Relevant academic research and scientific papers

TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.

NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF

The new 1H-furo[3,2-b]imidazo[4,5-d]pyridine derivatives are selective Jak1 kinase inhibitors useful in treating disorders related to Jak1 activities such as autoimmune diseases or disorders, inflammatory diseases or disorders, and cancer or neoplastic di

Synthesis method of moCys section of marine natural product apratoxin E

The invention relates to a synthesis method of moCys section of a marine natural product apratoxin E, and belongs to the field of chemical synthesis. The moCys section (C27 to C30 section) of the marine natural product apratoxin E is prepared from cheap a

PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO

This invention relates to processes for preparing a JAKl inhibitor having Formula la: as well as new forms of the inhibitor.

New approach toward the total synthesis of (+)-batzellaside B

A new synthetic approach to (+)-batzellaside B from naturally abundant L-pyroglutamic acid is presented in this article. The key synthetic step involves Sharpless asymmetric dihydroxylation of an olefinic substrate functionalized with an acetoxy group to

RENIN INHIBITORS

Disclosed are aspartic protease inhibitors represented by the following structural formula: and pharmaceutically acceptable salts thereof. These compounds are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the t

Copper(I) mediated cross-coupling of amino acid derived organozinc reagents with acid chlorides

This paper describes the development of a straightforward experimental protocol for copper-mediated cross-coupling of amino acid derived β-amido-alkylzinc iodides 1 and 3 with a range of acid chlorides. The present method uses CuCN·2LiCl as the copper source and for organozinc reagent 1 the methodology appears to be limited to reaction with more stable acid chlorides, providing the desired products in moderate yields. When applied to organozinc reagent 3, however, the protocol is more general and provides the products in good yields in all but one of the cases tested. The Royal Society of Chemistry 2006.

HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Aminopurine Compounds having the following structure: (I) wherein R1 , R2 and and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

COMBINATION THERAPY WITH INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE AND ALKYLATING AGENTS

A combination therapy comprising administration of a carbamoylating chemotherapeutic agent in conjunction with administration of a selective iNOS inhibitor compound is disclosed. Optionally, resection and radiation therapy are provided with the therapeutic combination. A medicament comprising a carbamoylating chemotherapeutic agent and a selective iNOS inhibitor compound together with a pharmaceutically acceptable carrier is further disclosed. A kit comprising a carbamoylating chemotherapeutic agent and a selective iNOS inhibitor compound is further disclosed.

METHODS FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL CONDITIONS

Therapeutic methods for the prevention ad treatment of conditions and diseases of the gastrointestinal tract involving an overproduction of nitric oxide by inducible nitric oxide synthase are described, the methods including administering to a subject in need thereof a therapeutically effective amount of a selective inhibitor of inducible nitric oxide synthase (iNOS). The methods also include the use of selective inhibitors of iNOs in combination with other therapeutic agents, including antimicrobial agents and antisecretory agents.